Issue Date: April 13, 2009
BMS Expands Dealings With Otsuka
Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have expanded an existing development and commercialization deal and set up a new one in oncology. The two companies have extended their deal for the antipsychosis drug Abilify by three years to 2015. They will also jointly develop and sell the BMS oncology products Sprycel and Ixempra. BMS will pay Otsuka $400 million in cash up front and a share of product sales, and Otsuka will contribute to commercialization expenses.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society